Alzecure Pharma Ab · OMXSTO:ALZCUR
Alzecure Pharma Ab — Investor Presentation (August 2025)
12 slides from Alzecure Pharma Ab's investor presentation, Aug 27, 2025
Slide 1: Painless ACD440 - An Opportunity in Erythromelalgia
August 27, 2025 Painless ACD440 - An Opportunity in Erythromelalgia Märta Segerdahl, MD, PhD, CMO
Slide 2: What is Erythromelalgia?
What is Erythromelalgia? • Erythromelalgia is a rare chronic painful disorder - ”burning feet syndrome” • Triad of redness, swelling and intense pain • Pain comes in attacks, flares, triggered by heat or exercise • One flare can last for an hour and up to days • Divided into Primary erythromelalgia,
Slide 3: How does erythromelalgia appear and how common is it?
How does erythromelalgia appear and how common is it? • The prevalence of Erythromelalgia, primary and secondary together, is approximately 13/ 100,000, i.e. an orphan disease • In the US, between 43,000 and 70,000 individuals* are estimated to have Erythromelalgia (Orphan = <200,000 patients) • Sta
Slide 4: Erythromelalgia – the patient story
Erythromelalgia – the patient story Characteristics – a 2021 patient survey by TEA* • Symptoms in hereditary forms start by age 4-20, sporadic forms often in adult age. • Patients are most often diagnosed by neurologists, dermatologists or rheumatologists. Rarely by primary care. >1 year from contac
Slide 5: The TRPV1 receptor is key in pain signalling
The TRPV1 receptor is key in pain signalling • The TRPV1* receptor was characterized in the 1990’s and shown to be central for the mediation of heat and pain. • The Nobel prize 2021 was awarded to Prof. Julius for the Professor David Julius discovery of the TRPV1 receptor Nobel prize medicine laurea
Slide 6: TRPV1 – Target Mechanism Central to Pain Signaling
TRPV1 – Target Mechanism Central to Pain Signaling • The transient receptor potential cation channel subfamily V member 1 (TRPV1), or capsaicin receptor, plays a central role in the transduction of TrpV1 pain • It is widely distributed in the body, and in chronic painful conditions TRPV1 receptors a
Slide 7: What does an Orphan Drug Designation (ODD) add?
What does an Orphan Drug Designation (ODD) add? • ACD440 Gel is granted an Orphan Drug Designation (ODD) for the treatment of erythromelalgia by FDA • Pre-IND meeting with the FDA took place in Q2 – FDA very supportive of our development program • Benefits with an ODD designation • ODD is granted fo
Slide 8: ACD440 Gel effectively blocks the TRPV1 receptor reducing heat induced pain
ACD440 Gel effectively blocks the TRPV1 receptor reducing heat induced pain • Two studies have been conducted − In healthy subjects exposed to experimental pain, ACD440 Gel reduced heat induced pain by 50%, compared to placebo after 1 hour of application − In patients with chronic neuropathic pain w
Slide 9: Benefits with Orphan Drug Designation
Benefits with Orphan Drug Designation In general, smaller programs, lower risk and shorter time to market FDA EMA • Reduced cost for clinical trials – smaller • Free and frequent scientific advice for programs SMEs • Tax credits for qualified clinical trials • Waived fees for marketing submissions •
Slide 10: Going forward from here
Going forward from here • After having received the supporting feedback from the FDA, and been granted the ODD, we will now continue the preparations for a full development program in Erythromelalgia • We are focusing on optimizing the program design in all aspects • Aiming for the shortest time to
Slide 11: In summary
In summary • Erythromelalgia is a rare and chronic disease of all ages • Pain in Erythromelalgia is triggered by heat • ACD440 Gel is effective in reducing heat induced pain • The granted ODD shows that the FDA supports the rationale for the development of ACD440 in erythromelagia • Orphan designati
Slide 12: Karolinska Institutet Novum Science Park Hälsovägen 7, 141 57 Stockholm SWEDEN
Karolinska Institutet Novum Science Park Hälsovägen 7, 141 57 Stockholm SWEDEN www.alzecurepharma.com
AlzeCure Pharma — Investor Presentation (August 2025) on 6ix